Kolon TissueGene, Inc.

Languages

  • English
  • Korean
  • English
  • About
    • Overview
    • History
    • Management Team
    • Board of Directors
    • Advisory Boards
  • Technology
    • Overview
    • TG-C
    • Publications
  • Product Pipeline
    • Overview
    • Applications
  • Clinical Trials
  • IR
    • Stock Data
    • PR
    • IR Material
    • Disclosure
    • Analyst Report
  • Partnering/Alliances
  • Contact

PR

IR

IR

  • Stock Data
  • PR
  • IR Material
  • Disclosure
  • Analyst Report

KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS

Apr 28, 2025

코오롱티슈진, TG-C 골관절염 치료기술 일본 특허 취득

Jul 25, 2024

KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO PIVOTAL US PHASE III CLINICAL TRIALS FOR TG-C

Jul 11, 2024

코오롱티슈진, TG-C 美 FDA 3상 투약 성공적으로 완료

Jul 11, 2024

코오롱티슈진, 글로벌 골관절염 학회(IWOAI)에서 DMOAD 가능성 시사

Jul 5, 2024

코오롱티슈진, 세계적인 골관절염학회에서 임상 데이터 기반 TG-C의 안전성 및 유효성 소개

Apr 25, 2024

코오롱티슈진, 러시아서 TG-C 척추 적응증 특허 취득

Apr 9, 2024

코오롱티슈진, TG-C 척추 적응증 FDA 임상시험 승인

Dec 19, 2023

코오롱티슈진, TG-C 골관절염 치료기술 중국 특허 취득

Nov 3, 2023

코오롱티슈진, 글로벌 골관절염 학회(IWOAI)에서 TG-C 우수성 강조

Jul 5, 2023
  • 1
  • 2
  • 3
  • 4
© 2025 Kolon TissueGene, Inc. All Rights Reserved.

This information—including product information—is intended only for residents of the United States. The products discussed on this site may have different labeling in different countries.

Privacy Policy Disclaimer Sitemap Ethical Management